FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United St…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Slate Medicines Starts Migraine Treatment Study By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge. | ||
 Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contributing its drug assets, while new investors are supplying $245 million. Legacy Slate holders would own approximately 55.9% of the combined company, PIPE investors 39.1%, and legacy Fulcrum holders 5%, […] | ||
 Fulcrum and Slate Medicines sign merger agreement After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline. | ||
 Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec | ||
 Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex S | ||
Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger Fulcrum Therapeutics (FULC) and Slate Medicines said Monday they have agreed to combine in an all-st | ||
 Slate, Fulcrum to combine in reverse merger Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug. | ||
 Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set... | ||